Last reviewed · How we verify
Zovaglutide
Zovaglutide is a Small molecule drug developed by Beijing QL Biopharmaceutical Co.,Ltd. It is currently in Phase 3 development. Also known as: ZT002 Injection.
Zovaglutide is a medication being studied for the treatment of overweight and obesity. It is administered in different doses as part of clinical trials to evaluate its safety and efficacy in these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Zovaglutide |
|---|---|
| Also known as | ZT002 Injection |
| Sponsor | Beijing QL Biopharmaceutical Co.,Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants (PHASE1)
- A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zovaglutide CI brief — competitive landscape report
- Zovaglutide updates RSS · CI watch RSS
- Beijing QL Biopharmaceutical Co.,Ltd portfolio CI
Frequently asked questions about Zovaglutide
What is Zovaglutide?
Who makes Zovaglutide?
Is Zovaglutide also known as anything else?
What development phase is Zovaglutide in?
Related
- Manufacturer: Beijing QL Biopharmaceutical Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: ZT002 Injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing